Cardinal Health CIO Michelle Greene Sells 11,650 Shares for $2.7M While Retaining $2.43M Stake Post-Sale

The Quick Take

• Cardinal Health CIO Michelle Greene sold 11,650 shares at a weighted average of $235.72 per share on August 18, generating approximately $2.7 million in proceeds.
• Greene retained 10,330 shares worth approximately $2.43 million after the sale, maintaining material personal exposure to Cardinal Health's stock performance.
• The CIO sale is part of a broader pattern of Cardinal Health senior executives monetising gains on August 18, following the stock's 57% one-year appreciation.

Cardinal Health's Chief Information Officer Michelle Greene filed a Form 4 disclosing the sale of 11,650 shares at a weighted average price of $235.72 per share on August 18, 2026, generating total proceeds of approximately $2.74 million. The transaction is notable for its timing — August 18 is also the date of multiple other Cardinal Health executive transactions, including the CEO's multi-day disposal programme and the CFO's approximately $9.9 million sale, suggesting a coordinated window for planned selling across the C-suite. Greene's retained position of 10,330 shares, valued at approximately $2.43 million at current prices, represents substantial continued personal stake in the company's equity performance.

For a Chief Information Officer at a major healthcare distribution company, Greene's sale is contextually smaller than CEO and CFO transactions but reflects the same underlying dynamic: significant stock appreciation (57% over one year) creates concentrated positions in executive equity that benefit from periodic rebalancing. CIOs at large healthcare companies are typically compensated with equity awards tied to digital transformation milestones, technology cost reduction programmes, and cybersecurity performance metrics. Greene's retention of 10,330 shares — nearly the equivalent value to the amount sold — signals she is not reducing exposure below her target long-term holding, consistent with a tax-management or diversification transaction rather than a negative outlook signal.

The forward signal to watch is whether Greene or other Cardinal Health executives file additional Form 4 transactions in Q3 2026, particularly at current price levels that remain elevated relative to historical averages. The macro variable for Cardinal Health broadly is the US healthcare system's prescription drug distribution regulation — Cardinal Health's CIO role specifically involves the technology infrastructure supporting pharmaceutical order management, compliance, and cold chain tracking, which are areas subject to increasing regulatory scrutiny under FDA and DEA frameworks. Any technology-driven compliance failure or data breach would be a CIO-level accountability risk that Cardinal Health equity investors track.

Synthesized from 2 sources.